

Certificate of Analysis

PI 3-Kinase (p110 α /p85 α), murine (Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-785, 14-785-K, 14-785M

Parent Lot # D8HN028U

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: Complex of N-terminal 6His-tagged, recombinant, full-length mouse p110 α and untagged, recombinant, full-length mouse p85 α . Co-expressed by baculovirus in Sf21 insect cells and purified using Ni²⁺/NTA-agarose.

Purity (p110 α & p85 α combined) 82.5% by SDS-PAGE and Coomassie blue staining. p110 α MW = 129kDa, p85 α MW = 83.6kDa.

Specific Activity (Parent lot# D8HN028U): 186U/mg, where one unit of PI 3-Kinase alpha (p110 α /p85 α) activity is defined as 1nmol phosphatidylinositol 3,4,5-trisphosphate (PIP3) formed per minute at room temperature with a final ATP concentration of 100 μ M.

Formulation: 1.777mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 0.2mM PMSF, 1mM benzamidine, 0.1% 2-mercaptoethanol. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.

**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 0.2–8ng of this enzyme phosphorylated 10 μ M phosphatidylinositol 4, 5-bisphosphate in the assay referenced on page two



MS Tryptic Fingerprint: Confirmed identity as PI 3-Kinase (p110 α /p85 α) with the p110 α and p85 α translated sequence listed on pages three and five.

SDS-PAGE and Coomassie Stain: Purity was assessed by SDS-PAGE and Coomassie blue staining using 3 μ g of active PI 3-Kinase (p110 α /p85 α)



Certificate of Analysis

Eurofins PI3 Kinase Homogeneous Time-resolved Fluorescence (HTRF) Class I Reagent Kits

The following Eurofins kits are suitable for use with this enzyme:

Cat. No	Kit Description
33-016	PI3 Kinase 4-Step Assay Reagent 1-Plate Kit
33-017	PI3 Kinase 4-Step Assay Reagent 5-Plate Kit
33-036	PI3 Kinase 4-Step Assay Reagent Kit (10000 wells)
33-037	PI3 Kinase 4-Step Assay Reagent Kit (50000 wells)
33-040	PI3 Kinase 3-Step Assay Reagent Kit (384 wells)
33-041	PI3 Kinase 3-Step Assay Reagent Kit (1920 wells)
33-047	PI3 Kinase 3-Step Assay Reagent Kit (10000 wells)

Kits 33-016, 33-017, 33-036 and 33-037 provide reagents and assay details for the Eurofins standard 4-step HTRF assay. This assay format is suitable for the majority of small and medium throughput screening work. The 3-step HTRF assay (kits 33-040, 33-041, 33-047) was introduced to reduce the number of assay steps to aid high throughput screening. Items 33-040 and 33-041 are intended as introductory kits for 3-step procedure work up. Please contact us for any further information regarding different kit formats (discoveryservices@eurofins.com).

Certificate of Analysis

p110 α Sequence Information

<u>Protein</u>	Murine p110 α
<u>Tags</u>	N-terminal 6His
<u>Native sequence</u>	M37 of the recombinant sequence is equivalent to M1 of murine p110 α
<u>Accession number</u>	GenBank BC089038

Recombinant p110 α amino acid sequence:

```

1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF KGLRRQMPPR PSSGELWGIH LMPPRILVEC
61 LLPNGMIVTL ECLREATLVT IKHELFRER KYPLHQLLQD ETSYIFVSVT QEAEREFFFD
121 ETRRLCDLRL FQPFLKVIEP VGNREEKILN REIGFVIGMP VCEFDMVKDP EVQDFRRNIL
181 NVCKEAVDLR DLNSPHSRAM YVYPPNVESS PELPKHIYNK LDKGQIIIVI WVIVSPNNDK
241 QKYTLKINH CVPEQVIAEA IRKKTRSMML SSEQLKLCVL EYQGYILKV CGCDEYFLEK
301 YPLSQYKYIR SCIMLGRMPN LMLMAKESLY SQLPIDSFTM PSYSRRISTA TPYMNGETST
361 KSLWVINSAL RIKILCATYV NVNIRDIDKI YVRTGIYHGG EPLCDNVNTQ RVPCSNPRWN
421 EWLNYDIYIP DLPRAARLCL SICSVKGRKG AKEEHCPLAW GNINLFDYTD TLVSGKMALN
481 LWPVPHGLED LLNPIGVTGS NPNKETPCLE LEFDWFSSV KFPDMSVIEE HANWSV SREA
541 GFSYSHTGLS NRLARDNELR ENDKEQLRAL CTRDPLSEIT EQEKDFLWSH RHYCVTIPEI
601 LPKLLLSVKW NSRDEVAQMY CLVKDWPPIK PEQAMELLDC NYPDPMVRSF AVRACLEKYL T
661 DDKLSQYLIQ LVQVLKYEQY LDNLLVRFLL KKALTNQRIG HFFFWHLKSE MHNKTVSQRF
721 GLLLESYCRA CGMYLKHLNR QVEAMEKLIN LTDILKQEKK DETQKVQMKF LVEQMRQPDF
781 MDALQGFLSP LNP AHQLGNL RLEECRIMSS AKRPLWLNWE NPDIMSELLF QNNEIIFKNG
841 DDLRQDMLTL QIIRIMENIW QNQLDLRML PYGCLSIGDC VGLIEVVRNS HTIMQIQCKG
901 GLK GALFNS HTLHQWLKDK NKGEIYDAAI DLFTRSCAGY CVATFILGIG DRHNSNIMVK
961 DDGQLFHIDF GHFLDHKKKK FGYKRERVPF VLTQDFLIVI SKGAQEYTKT REFERFQEMC
1021 YKAYLAIRQH ANLFINLFSM MLGSGMPELQ SFDDIAYIRK TLALDKTEQE ALEYFTKQMN
1081 DAHHGGWTK MDWIFHTIKQ HALN
    
```

Recombinant p110 α nucleotide sequence:

```

1 atgtcgtact accatcacca tcaccatcac gattacgata tcccaacgac cgaaaacctg
61 tattttcagg gcgccatgga tccggaattc aaaggcctac gtcgacaaat gcctccacga
121 ccatcttcgg gtgaactgtg gggcatccac ttgatgcccc cacgaatcct agtggaatgt
181 ttactcccca atggaatgat agtgacttta gaatgcctcc gtgaggccac actcgtcacc
241 atcaaacatg aactgttcag agaggccagg aaataccctc tccatcagct tctgcaagac
301 gaaacttctt acattttcgt aagtgtcacc caagaagcag aaagggaga atttttgat
361 gaaacaagac gactttgtga ccttcggctt tttcaaccct ttttaaaagt tattgaacca
421 gtaggcaacc gtgaagaaa gatcctcaat cgagaaattg gttttgttat tggcatgcca
481 gtgtgtgaat ttgatatggt taaagatcca gaagtccaag actttcgaag gaacattctg
541 aatgtttgca aagaagctgt ggacctgcgg gatctcaact cgctcatag cacagcaatg
601 ttatgtctacc ctccaaatgt cgagtcttcc ccagaactgc caaagcacat ctacaacaag
661 ttagataaag gacaaatcat agtggtgatt tgggtaatag tctctccaaa caacgacaag
721 cagaagtaca ctctgaagat caatcatgac tgtgtgccag agcaagtcac tgctgaagcc
781 atcaggaaaa agactcggag catgttggtg tcctctgagc agctgaaact ctgtgtctta
841 gaatatcagg gcaagtatat tctgaaagtg tgtggctgtg acgaatactt cctggaaaag
901 taccctctga gtcagtacaa gtacataaga agctgtataa tgctggggag gatgccaac
961 ttgatgctga tggccaaaga aagcctatac tctcagctgc cgattgatag cttcaccatg
1021 ccgtcatact ccaggcgcac ctccacagcc acaccctaca tgaatggaga gacatctacg
1081 aatccctctt gggtcataaa tagtgcgctc agaataaaaa ttctttgtgc aacctatgta
1141 aatgtaaata ttcgagacat tgataagatc tatgttcgaa caggtatcta ccatggagga
    
```

Certificate of Analysis

1201 gaacccttat gtgacaatgt gaacactcaa agagtacctt gttccaatcc taggtggaat
1261 gaatggctga attatgatat atacattcct gatcttcctc gtgctgcgcg cctttgcctt
1321 tcaatctgct ctgttaaagg ccgaaaggtt gctaaggagg agcactgtcc gttggcctgg
1381 ggaaacataa acttgtttga ttatacagac accctagtgt ccgggaaaaat ggctttgaat
1441 ctctggcctg taccgcatgg gttagaagat ctgctgaacc ctattggtgt tactgggtca
1501 aatccaaata aagaaaactcc atgcttagag ttggagtttg attggttcag cagtgtggtg
1561 aagtttccag acatgtctgt gatcgaagaa catgcccaatt ggtccgtgtc ccgagaagct
1621 ggattcagtt actcccatac aggactgagt aacagactag ccagagacaa tgagttaaga
1681 gaaaatgaca aggaacagct ccgagcactt tgcacccggg acccactatc tgaaatcact
1741 gaacaagaga aagacttcct atggagccac agacactact gcgtaactat tcctgaaatc
1801 ctacccaaat tgcttctgtc tgtcaagtgg aattccagag acgaagtggc ccagatgtac
1861 tgcttagtaa aagattggcc tccaatcaaa ccagagcaag ccatggaact cctggactgt
1921 aactatccag atcctatggt tcggagtttt gctgttcggt gcttagaaaa atatttaaca
1981 gatgacaaac tttctcagta cctcattcaa cttgtacagg tcttaaaata tgaacagtat
2041 ttggataacc tgcttgtgag atttttactc aagaaagcat tgacaaatca aaggattggc
2101 cattttttct tttggcattt aaaatctgag atgcacaata agactgtcag tcagaggttt
2161 ggctgctat tggagtccta ctgccgtgcc tgtgggatgt atctgaagca cctgaacaga
2221 caagtagagg ccatggagaa gctcatcaac ctaacggaca tccttaagca ggagaagaag
2281 gatgagacac aaaaggtaca gatgaagttt ttggttgaac agatgagaca gccagacttc
2341 atggatgctt tgcagggttt tctgtcccct ctgaatcctg ctcaccaact aggaaacctc
2401 aggcttgaag agtgtcgaat tatgtcctct gcaaaaaggc cactgtgggt gaattgggag
2461 aaccagaca tcatgtcaga gctactgttt cagaacaatg agatcatctt taaaaatggc
2521 gacgacttac ggcaagatat gttaacctt cagatcatcc gaatcatgga gaacatctgg
2581 caaaaccaag gccttgacct tcgcatgcta ccttatggct gtctatccat tggggactgt
2641 gtgggtctca tcgaggtggt gagaaactct cacacatca tgcaaatcca gtgcaaagga
2701 ggctgaagg gggcgctgca gttcaacagc cacacactgc atcaatggct caaggacaag
2761 aacaagggcg agatatatga tgcagccatt gacctgttca ctcggtcctg cgctgggtac
2821 tgcgtggcaa cctttatctt ggaattgga gaccggcaca acagcaacat catggtgaaa
2881 gatgacggac agctgttcca tatagatttt gggcactttt tggatcacia gaagaaaaaa
2941 tttggctata agcgggaacg tgtgccattt gtggtgacac aggatttctt gattgtgatt
3001 agtaaggag cacaagagta caccaagacc agagagtttg agaggtttca ggagatgtgt
3061 tacaaggctt acctagcaat tcggcagcat gccaatctct tcatcaacct tttttcaatg
3121 atgcttggct ctggaatgcc agaactacia tcttttgatg acattgcata tatccgaaag
3181 actctagcct tggacaaaac tgagcaagaa gctttggaat atttcacaaa gcaaatgaat
3241 gatgcacatc atggtggatg gacgacaaaa atggattgga tcttccacac catcaagcag
3301 catgctttga actaa

Certificate of Analysis

p85α Sequence Information

<u>Protein</u>	Murine p85α
<u>Tags</u>	Untagged
<u>Native sequence</u>	M1 of the recombinant protein is equivalent to M1 of murine p85α
<u>Accession number</u>	GenBank NM_001077495

Recombinant p85α amino acid sequence:

```

1 MSAEGYQYRA  LYDYKKEREE  DIDLHLGDIL  TVNKGSLVAL  GFSDBGQEARP  EDIGWLNQYN
61 ETTGERGDFP  GTYVEYIGRK  RISPPTPKPR  PPRPLPVAPG  SSKTEADTEQ  QALPLPDLAE
121 QFAPPDVAPP  LLIKLEAIE  KKGLECSTLY  RTQSSSNPAE  LRQLLDCDAA  SVDLEMIDVH
181 VLADAFKRYL  ADLNPVPIPV  AVYNEMMSLA  QELQSPEDCI  QLLKKLIRLP  NIPHQCWLTL
241 QYLLKHFFKL  SQASSKNLLN  ARVLS EIFSP  VLFRFPAASS  DNTEHLIKAI  EILISTEWNE
301 RQPAPALPPK  PPKPTTVANN  SMNNNMSLQD  AEWYWGDISR  EEVNEKLRDT  ADGTFLVRDA
361 STKMHGDYTL  TLRKGGNKL  IKIFHRDGKY  GFSDPLTFNS  VVELINHYRN  ESLAQYNPKL
421 DVKLLYPVSK  YQQDQVVKED  NIEAVGKKLH  EYNTQFQEK  REYDRLYEY  TRTSQEIQMK
481 RTAIEAFNET  IKIFEEQCQT  QERYKEYIE  KFKREGNEKE  IQRIMHNHDK  LKSRISEIID
541 SRRRLEEDLK  KQAAEYREID  KRMNSIKPDL  IQLRKTRDQY  LMWLTQKQVR  QKKLNEWLGN
601 ENTEDQYSLV  EDEDLPHHD  EKTWNVSSN  RNKAENLLRG  KRDTGFLVRE  SSKQGCYACS
661 VVVDGEVKHC  VINKTATGYG  FAEPYNLYSS  LKELVLHYQH  TSLVQHNSDL  NVTLAYPVYA
721 QRR

```

Recombinant p85α nucleotide sequence:

```

1 atgagtgctg aggggtacca gtacagagca ctgtacgact acaagaagga gcgagaggaa
61 gacattgacc tacacctggg ggacatactg actgtgaata aaggctcctt agtggcactt
121 ggattcagtg atggccagga agcccggcct gaagatattg gctggttaaa tggctacaat
181 gaaaccactg gggagagggg agactttcca ggaacttacg ttgaatacat tgggaaggaaa
241 agaatttcac cccctactcc caagcctcgg ccccctcgac cgcttcctgt tgctccgggt
301 tcttcaaaaa ctgaagctga cacggagcag caagcgttgc cccttcctga cctggccgag
361 cagtttgccc ctctgatgt  tgccccgct  ctccttataa agctcctgga agccattgag
421 aagaaaggac tggaatgtt  gactctatac agaacacaaa gctccagcaa ccctgcagaa
481 ttacgacagc ttcttgatt  tgatgccgcg tcagtggact tggagatgat cgacgtacac
541 gtcttagcag atgctttcaa acgctatctc gccgacttac caaatcctgt cttcctgta
601 gctgtttaca atgagatgat gtcttttagc caagaactac agagccctga agactgcac
661 cagctgttga agaagctcat tagattgctt aatatacctc atcagtgttg gcttacgctt
721 cagtatttgc tcaagcatt  tttcaagctc tctcaagcct ccagcaaaaa ccttttgaat
781 gcaagagtcc tctctgagat tttcagcccc gtgcttttca gatttccagc gccagctct
841 gataatactg aacacctcat aaaagcgata gagattttaa tctcaacgga atggaatgag
901 agacagccag caccagcact gcccccaaaa ccaccaagc  ccactactgt agccaacaac
961 agcatgaaca acaatatgtc cttgcaggat gctgaatgg  actggggaga catctcaagg
1021 gaagaagtga atgaaaaact cggagacact gctgatggga ctttttggg  acgagacgca
1081 tctactaaaa tgcacggcga ttacactctt aactaagga  aaggaggaaa taacaaatta
1141 atcaaaatct ttcaccgtga tggaaaatat ggcttctctg atccattaac cttcaactct
1201 gtggttgagt taataaacca ctaccggaat gagtctttag ctcagtacaa cccaagctg
1261 gatgtgaagt tgctctacc  agtgtccaaa taccagcagg atcaagttgt caaagaagat
1321 aatattgaag ctgtagggaa aaaattacat gaatataata ctcaatttca agaaaaaagt
1381 cgggaatatg atagattata tgaggagtac acccgtactt cccaggaaat ccaaatgaaa
1441 agaacggcta tcgaagcatt taatgaaacc ataaaaatat ttgaagaaca atgccaacc
1501 caggagcgg  acagcaaga  atacatagag  aagtttaaac  gcgaaggcaa  cgagaaagaa
1561 attcaaagga ttatgcataa ccatgataag ctgaagtcgc gtatcagtga gatcattgac
1621 agtaggagga ggttgaaga  agacttgaag  aagcaggcag  ctgagtaccg  agagatcgac

```

Certificate of Analysis

```
1681 aaacgcatga acagtattaa gccggacctc atccagttga gaaagacaag agaccaatac
1741 ttgatgtggc tgacgcagaa aggtgtgcgg cagaagaagc tgaacgagtg gctggggaat
1801 gaaaataccg aagatcaata ctccctggta gaagatgatg aggatttgcc ccaccatgac
1861 gagaagacgt ggaatgtcgg aagcagcaac cgaaacaaag cggagaacct attgcgaggg
1921 aagcgagacg gcactttcct tgtccgggag agcagtaagc agggctgcta tgcctgctcc
1981 gtagtggtag acggcgaagt caagcattgc gtcattaaca agactgccac cggctatggc
2041 tttgccgagc cctacaacct gtacagctcc ctgaaggagc tggtgctaca ttatcaacac
2101 acctccctcg tgcagcacia tgactccctc aatgtcacac tagcataccc agtatatgca
2161 caacagaggc gataa
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.